MACC1-a novel target for solid cancers

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 9, 2013, Pages 1039-1052

  Stein, Ulrike ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b German Cancer Consortium ^*  (Germany)

Author keywords

Intervention; MACC1; Prediction; Prognosis; Solid cancer

Indexed keywords

BETA CATENIN; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; INTERLEUKIN 4; MICRORNA 1; MICRORNA 143; MITOGEN ACTIVATED PROTEIN KINASE 7;

BINDING SITE; BREAST CANCER; CANCER GROWTH; CANCER PREVENTION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL MOTILITY; COLON METASTASIS; COLORECTAL CANCER; DISTANT METASTASIS; ESOPHAGUS CANCER; GENE; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; LUNG CANCER; MACC1 GENE; METASTASIS FREE SURVIVAL; NASOPHARYNX CANCER; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PIGMENT EPITHELIUM; PLURIPOTENT STEM CELL; PREDICTIVE VALUE; PRIMARY TUMOR; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; STOMACH CANCER; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84882696086     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.815727     Document Type: Review

References (86)

1. Stein U, Schlag PM. Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 2007;176:61-80
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: globocan 2008. Int J Cancer 2010;127:2893-917
3. Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
4. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52
5. Sethi N, Kang Y. Unravelling the complexity of metastasis-molecular understanding and targeted therapies. Nat Rev Cancer 2011;11:735-48
6. Wanebo HJ, LeGolvan M, Paty PB, et al. Meeting the biologic challenge of colorectal metastases. Clin Exp Metastasis 2012;29:821-39
7. Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009;15:59-678.
8. Juneja M, Ilm K, Schlag PM, et al. Promoter identification and transcriptional regulation of the metastasis gene MACC1 in colorectal cancer. Mol Oncol 2013; doi: 10.1016/j.molonc.2013.05.003
9. Stein U, Smith J, Walther W, et al. MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle 2009;8:2467-9
10. Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103 Review on Met targeting strategies and their clinical relevance for human cancers.
11. Lemos C, Sack U, Schmid F, et al. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways. Curr Pharm Des 2012;19:841-63
12. Luraghi P, Schelter F, Kruger A, et al. The MET oncogene as a therapeutical target in cancer invasive growth. Front Pharmacol 2012;3:164
13. Raghav KPS, Eng C. Role of the MET-HGF axis in colorectal cancer: precepts and prospects. Colorectal Cancer 2012;1:329-41
14. Arlt F, Stein U. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol 2009;41:2356-9
15. Schmid F, Wang Q, Huska M, et al. SPON2, a newly identified transcriptional target gene of MACC1, is associated with colorectal cancer metastasis. Eur J Cancer 2012;48(Suppl 6):63-4
16. Schmid F, Wang Q, Huska MR, et al. S100P, a target gene of MACC1, contributes to colorectal cancer metastasis. Proc Am Ass Cancer Res 2013;54:416
17. Tokarz P, Blasiak J. The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol 2012;59:467-74
18. Migliore C, Martin V, Leoni VP, et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res 2012;18:737-47
19. Zhang Y, Wang Z, Chen M, et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer 2012;11:2320.
20. Chen J, Wang B. The role of miRNA-143 in colon cancer and therapeutic implications. Transl Gastrointest Cancer 2012;1:169-74
21. Kokoszynska K, Krynski J. Rychlewski L, et al. Unexpected domain composition of MACC1 links MET signaling and apoptosis. Acta Biochim Pol 2009;56:317-23
22. Stein U, Dahlmann M, Walther W. MACC1-more than metastasis? Facts and predictions about a novel gene. J Mol Med 2010;88:11-18
23. Voss M, Lettau M, Janssen O. Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening. BMC Immunol 2009;10:53
24. Greening DW, Kapp EA, Ji H, et al. Colon tumour secretopeptidome: insightsinto endogenous proteolytic cleavage events in the colon tumour microenvironment. Biochim Biophys Acta 2013; [Epub ahead of print]
25. Pichorner A, Sack U, Kobelt D, et al. In vivo imaging of colorectal cancer growth and metastasis by targeting MACC1 with shRNA in xenografted mice. Clin Exp Metastasis 2012;29:573-83
26. Choi DS, Choi DY, Hong BS, et al. Quantitative proteomics of extracellular vesicles derived from human primary and metastatic colorectal cancer cells. J Extracellular Vesicles 2012;1:18704
27. Zhang Y, Wang Z. The influence of MACC1 on liver metastasis from colon cancer cells. Tumor 2011;31:513-16
28. Galimi F, Torti D, Sassi F, et al. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res 2011;17:3146-5629.
29. Loo LW, Tiirikainen M, Cheng I, et al. Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype negative colon cancer. Genes Chromosomes Cancer 2013;52:450-66
30. Shirahata A, Shinmura K, Kitamura Y, et al. MACC1 as a marker for advanced colorectal carcinoma. Anticancer Res 2010;30:2689-92
31. Ashktorab H, Herrmann P, Razjouan H, et al. MACC1 expression as molecular marker in colorectal cancer. Proc Am Ass Cancer Res 2011;52:927
32. Isella C, Mellano A, Galimi F, et al. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann Surg 2013;257:1089-95
33. Boardman LA. Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Genome Med 2009;1:36
34. LeGolvan MP, Resnick M. Pathobiology of colorectal cancer hepatic metastases with an emphasis on prognostic factors. J Surg Oncol 2010;102:898-908
35. Zlobec I. Novel biomarkers for the prediction of metastasis in colorectal cancer. Expert Opin Med Diagn 2013;7:137-46
36. Nitsche U, Rosenberg R, Balmert A, et al. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. Ann Surg 2012;256:763-7137.
37. Reece-Smith A, Argent R, Onio D, et al. The role of epithelial to mesenchymal transitions (MET) in the establishment of colorectal liver metastases. A potential source of prognostic biomarkers. Br J Surgery 2010;97:S5
38. Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffinembedded tissue. J Clin Oncol 2011;29:4620-6
39. Wisniewski JR, Ostasiewicz P, Mann M. High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. J Proteome Res 2011;10:3040-9
40. Merlos-Suarez A, Barriga FM, Jung P, et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011;8:511-2441.
41. Kawamura M, Saigusa S, Toiyama Y, et al. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res 2012;32:1527-31
42. Stein U, Burock S, Herrmann P, et al. Circulating MACC1 transcripts in colorectal cancer patient plasma predict metastasis and prognosis. PLoS One 2012;7:e4924943.
43. Toiyama Y, Miki C, Inoue Y, et al. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer 2009;125:1657-62
44. Lang AH, Geller-Rhomberg S, Winder T, et al. A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients. BMC Cancer 2012;12:20
45. Lang S, Geller-Rhomberg T, Winder BL, et al. Evaluation of the association between tagging polymorphisms of the MACC1 locus and overall survival in patients with colorectal cancer. ACSO Meeting. J Clin Oncol 2011;29(Suppl):abstracts 359446.
46. Schmid F, Burock S, Klockmeier K, et al. SNPs in the coding region of the metastasis-inducing gene MACC1 and clinical outcome in colorectal cancer. Mol Cancer 2012;11:49
47. Shirahata A, Sakata M, Kitamura Y, et al. MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res 2010;30:3441-4
48. Wang L, Wu Y, Lin L, et al. MACC1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion. Int J Cancer 2013; [Epub ahead of print]
49. Wang N, Xie JM, Zheng DY, et al. Establishment of BGC-823/pBaBb-puro- MACC1 gastric cancer cell line stably expressing MACC1 and its tumor-related gene expression profiles. Nan Fang Yi Ke Da Xue Xue Bao 2012;32:312-16
50. Ge SH, Wu XJ, Wang XH, et al. Over-expression of metastasis-associated in colon cancer-1 (MACC1) associates with better prognosis of gastric cancer patients. Chin J Cancer Res 2011;23:153-9
51. Wang G, Kang MX, Lu WJ, et al. MACC1: a potential molecule associated with pancreatic cancer metastasis and chemoresistance. Oncol Lett 2012;4:783-91
52. Stein U, Herrmann P, Fischer C, et al. Circulating MACC1 transcripts are elevated in pancreatic cancer patient blood and correlate to locally advanced disease. Proc Am Ass Cancer Res 2013;54:5106
53. Shirahata A, Fan W, Sakuraba K, et al. MACC 1 as a marker for vascularinvasive hepatocellular carcinoma. Anticancer Res 2011;31:777-80
54. Qiu J, Huang P, Liu Q, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med 2011;9:166
55. Qu JH, Chang XJ, Lu YY, et al. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2012;18:2995-3003
56. Gao J, Ding F, Liu Q, et al. Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem 2013;376:21-32
57. Xie C, Wu J, Yun J, et al. MACC1 as a prognostic biomarker for early-stage and AFP-normal hepatocellular carcinoma. PLoS One 2013;8:e64235
58. Yang YP, Qu JH, Chang XJ, et al. High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. J Transl Med 2013;11:41
59. Subrungruang I, Thawornkuno T, Chawalitchewinkoon-Petmitr R, et al. Gene expression profiling of intrahepatic cholangiocarcinoma. Asian Pacific J Cancer Prevention 2013;14:557-63
60. Shimokawa H, Uramoto H, Onitsuka T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg 2011;141:895-8
61. Chundong G, Uramoto H, Onitsuka T, et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 2011;31:1141-5
62. Hu X, Fu X, Wen S, et al. Prognostic value of MACC1 and c-met expressions in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2012;15:399-403
63. Saintigny P, Zhang L, Girard L, et al. Use of an EGFR mutation signature to estimate prognosis in EGFR wild-type lung adenocarcinomas and identify metastasis associated in colon cancer 1 (MACC1) as a regulator of MET [abstract 121]. ASCO Meeting Molecular Markers; 2010
64. Zhang R, Shi H, Chen Z, et al. Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. J Exp Clin Cancer Res 2011;30:83
65. Huang H, Shi H, Zhang R, et al. Expr'ssion of MACC1 in epithelial ovarian cancer and its clinical significance. Tumor 2011;31:522-6
66. Huang Y, Zhang H, Cai J, et al. Overexpression of MACC1 and its significance in human breast cancer progression. Cell Biosci 2013;3:16
67. Leth-Larsen R, Terp MG, Christensen AG, et al. Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis. Mol Med 2012;18:1109-21
68. Stein U, Fuchs S, Monoranu CM, et al. MACC1 expression as biomarker for progression and prognosis of human malignant glioma. Proc Am Ass Cancer Res 2012;53:107
69. Yang TH, Kon M, Hung JH, DeLisi C. Combinations of newly confirmed glioma-associated loci link regions on chromosomes 1 and 9 to increased disease risk. BMC Med Genomics 2011;4:63
70. Amlin-Van Schaick JC, Kim S, DiFabio C, et al. Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr12. Neuro Oncol 2012; 14: 160-74
71. Meng F, Li H, Shi H, et al. MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/b-catenin signaling pathway. PLoS One 2013;8:e60821
72. Shang C, Zhang H, Song Y. MACC1 gene and kidney cancer metastasis and its effect on cell invasion. Modern Oncol 2011;4:637-9
73. Shang C, Zhang H, Song Y-S. Regulation between MACC1 and c-Met in proliferative process of renal carcinoma. Chin J Cancer Prevention Treatment 2011;18:1065-7+87
74. Becker H, Marcucci G, Maharry K, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010;116:788-92
75. Zhu M, Xu Y, Mao X, et al. Overexpression of metastasis-associated in colon cancer-1 associated with poor prognosis in patients with esophageal cancer. Pathol Oncol Res 2013; [Epub ahead of print]
76. Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 2013;35:229-44
77. Elding H, Lau W, Swallow DM, et al. Refinement in localization and identification of gene regions associated with crohn disease. Am J Hum Genet 2013;92:107-13
78. El Chartouni C, Rehli M. Comprehensive analysis of TLR4-induced transcriptional responses in interleukin 4-primed mouse macrophages. Immunobiology 2010;215:780-7
79. Ali G, Lee K, Andrade PB, et al. Novel autosomal recessive nonsyndromic hearing impairment locus DFNB90 maps to 7p22.1-p15.3. Hum Hered 2011;71:106-12
80. Khanobdee K, Kolberg JB, Dunlevy JR. Nuclear and plasma membrane localization of SH3BP4 in retinal pigment epithelial cells. Mol Vis 2004;10:933-42
81. Dunlevy JR, Koppelman ED, Kolberg JB. The expression of a SH3BP4-related protein in retinal cells. Invest Ophthalmol Vis Sci 2005;46:2996
82. Yin J, Shine L, Raycroft F, et al. Inhibition of the Pim1 oncogene results in diminished visual function. PLoS ONE 2012;7:e52177
83. Melvin VS, Feng W, Hernandez-Lagunas L, et al. A morpholino-based screen to identify novel genes involved in craniofacial morphogenesis. Dev Dyn 2013; [Epub ahead of print]
84. Lin M, Pedrosa E, Shah A, et al. RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding rnas involved in neurogenesis and neuropsychiatric disorders. PLoS ONE 2011;6:e23356
85. Ligthart L, de Vries B, Smith AV, et al. Meta-analysis of genome-wide association for migraine in six population-basedEuropean cohorts. Eur J Hum Genet 2011;19:901-7
86. Hager J, Kamatani Y, Cazier JB, et al. the FGENTCARD Consortium. Genome-wide association study in a lebanese cohort confirms PHACTR1 as a major determinant of coronary artery stenosis. PLoS One 2012;7:e38663